<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> <z:chebi fb="0" ids="29425">(SCN)</z:chebi> is a hematologic condition characterized by arrested maturation of myelopoiesis at the promyelocyte stage of development </plain></SENT>
<SENT sid="1" pm="."><plain>With appropriate treatment using recombinant human granulocyte-colony-stimulating factor (r-HuG-CSF), <z:chebi fb="0" ids="18022">SCN</z:chebi> patients are now surviving longer, but are at increased risk of developing <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>)/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Hematopoietic stem cell transplantation (HSCT) is the only curative option for these patients, but transplantation outcomes after <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> are not well established </plain></SENT>
<SENT sid="3" pm="."><plain>We report results for six patients with <z:chebi fb="0" ids="18022">SCN</z:chebi> who underwent HSCT for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> between 1997 and 2001 at two transplant centers </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients transplanted for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> survived </plain></SENT>
<SENT sid="5" pm="."><plain>Both of these patients were transplanted without being given induction chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>Four patients, who <z:hpo ids='HP_0000001'>all</z:hpo> received induction chemotherapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> prior to HSCT, died </plain></SENT>
<SENT sid="7" pm="."><plain>Administering induction chemotherapy prior to HSCT resulted in significant morbidity </plain></SENT>
<SENT sid="8" pm="."><plain>Rapid transplantation should be the goal for the <z:chebi fb="0" ids="18022">SCN</z:chebi> patient once the diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> is established </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="18022">SCN</z:chebi> patients should be monitored carefully for progression to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> in order to be treated with HSCT as soon as they have progressed and before developing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>For <z:chebi fb="0" ids="18022">SCN</z:chebi> patients who progress to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, HSCT should still be considered, even though the risks appear to be greater </plain></SENT>
</text></document>